Letters to the Editor

• Simultaneous percutaneous repair in mitral and tricuspid regurgitation: step by step. Response

  Rodrigo Estévez-Loureiro, Berenice Caneiro-Queija, José Antonio Baz, Andrés Íñiguez-Romo

  Rev Esp Cardiol. 2020;73:1086-7

• Prothrombosis in times of COVID-19

  Iñigo Pereiro Lili, Ainara Lozano Bahamonde, Nora García Ibarrondo

  Rev Esp Cardiol. 2020;73:1087-9

• New words, not always clearer

  Jordi Delás

  Rev Esp Cardiol. 2020;73:1089

• Exercise-based cardiac rehabilitation in COVID-19 times: one small step for health care systems, one giant leap for patients

  Fernando Ribeiro, Mário Santos

  Rev Esp Cardiol. 2020;73:969-70

• Cardiac magnetic resonance characterization of COVID-19 myocarditis

  Meylin Caballeros Lam, Ana de la Fuente Villena, Aitor Hernández Hernández, Manuel García de Yébenes, Gorka Bastarrika Alemañ

  Rev Esp Cardiol. 2020;73:863-4

• Fulminant myocarditis and COVID-19

  Beuy Joob, Viroj Wiwanitkit

  Rev Esp Cardiol. 2020;73:865

• Tendencies in cause of death in patients with chronic heart failure and depressed systolic function

  Pedro Moliner, Josep Lupón

  Rev Esp Cardiol. 2020;73:783-4

• Tendencies in cause of death in patients with chronic heart failure and depressed systolic function. Response

  Domingo A. Pascual Figal, David Fernández-Vázquez

  Rev Esp Cardiol. 2020;73:784-5

• The sample size myth

  José Abellán-Huerta, Luis Prieto-Valiente

  Rev Esp Cardiol. 2020;73:785-6

• Designs and methods for impact evaluation of interventions

  Antonio Sarria-Santamera

  Rev Esp Cardiol. 2020;73:689

• Designs and methods for impact evaluation of interventions. Response

  Guillermo Aldama, Javier Muñiz

  Rev Esp Cardiol. 2020;73:690

• 116? How much should LDL-C be lowered in the «low risk» population?

  Juan Carlos Aguirre Rodríguez

  Rev Esp Cardiol. 2020;73:690-1

• COVID-19 and treatment guided by biochemical and molecular diagnostic tests to reduce myocardial damage and cardiotoxicity

  Sonia Eiras, Ezequiel Álvarez, María Brión, José Ramón González-Juanatey

  Rev Esp Cardiol. 2020;73:691-3

• Living evidence in response to controversies about the use of antimalarials in COVID-19

  Azucena Santillán-García, Rocío Bravo-Jeria, Francisca Verdugo-Paiva, Gabriel Rada

  Rev Esp Cardiol. 2020;73:693-4

• Cardio-onco-hematology patients’ management in the context of the current COVID-19 pandemic

  Rebeca Lorca, Reyes López Triviño, César Morís

  Rev Esp Cardiol. 2020;73:694-5

• Oxygen therapy and palliative care in patients with heart failure

  José Manuel Carratalá, Bárbara Peña-Pardo, Víctor Gil, Javier Jacob

  Rev Esp Cardiol. 2020;73:598

• Oxygen therapy and palliative care in patients with heart failure. Response

  José Manuel García-Pinilla, Pablo Díez-Villanueva, María G. Crespo Leiro, Clara Bonanad-Lozano

  Rev Esp Cardiol. 2020;73:599

• Administrative data and volume of surgical revascularization. A note of caution

  Javier Gualis Cardona, Elio Martín Gutiérrez, Mario Castaño Ruiz

  Rev Esp Cardiol. 2020;73:599-600

• Administrative data and volume of surgical revascularization volume. A note of caution. Response

  Francisco J. Elola, Cristina Fernández Pérez, José L. Bernal, F. Javier Goicolea Ruigómez

  Rev Esp Cardiol. 2020;73:600-1

• Controversy regarding ACE inhibitors / ARBs in COVID-19

  Federico Soria Arcos, Antonio Romero Puche, Tomás Vicente Vera

  Rev Esp Cardiol. 2020;73:516